Lundbeck CEO Braestrup sees double-digit growth in 2007
Forbes - We have moved a depression treatment candidate to Phase II and bought a Phase III candidate (nalmefene).' Nalmefene is used in the treatment of substance and impulse control disorders. Late last month, Finland's BioTie Therapies Oyj granted Lundbeck
Source: www.forbes.com
Click here for more information about depression screening depression screening
<< Home